Browse FCHO1

Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane, clathrin-coated pit Peripheral membrane protein Cytoplasmic side Note=Associated with forming but not mature clathrin-coated vesicles. The recruitment to coated-pits precede the one of clathrin and the adaptor protein complex AP-2. According to PubMed:17617719 it may also dynamically associate with Golgi/TGN membranes.
Domain PF00611 Fes/CIP4
PF10291 Muniscin C-terminal mu homology domain
Function

Functions in an early step of clathrin-mediated endocytosis. Has both a membrane binding/bending activity and the ability to recruit proteins essential to the formation of functional clathrin-coated pits. May regulate Bmp signaling by regulating clathrin-mediated endocytosis of Bmp receptors.

> Gene Ontology
 
Biological Process GO:0006898 receptor-mediated endocytosis
GO:0048268 clathrin coat assembly
GO:0072583 clathrin-dependent endocytosis
Molecular Function GO:0035612 AP-2 adaptor complex binding
Cellular Component GO:0005905 clathrin-coated pit
GO:0098589 membrane region
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-8856825: Cargo recognition for clathrin-mediated endocytosis
R-HSA-8856828: Clathrin-mediated endocytosis
R-HSA-199991: Membrane Trafficking
R-HSA-5653656: Vesicle-mediated transport
Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FCHO1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FCHO1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FCHO1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.0840.837
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0950.902
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.2120.748
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1320.798
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.270.874
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0450.983
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.8920.112
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.9360.306
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.960.298
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 482.0790.035
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.8690.224
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0730.586
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FCHO1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27737.41.460.177
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27597.41.75.70.231
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FCHO1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FCHO1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FCHO1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FCHO1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FCHO1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FCHO1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFCHO1
NameFCH domain only 1
Aliases KIAA0290; FCH domain only protein 1; F-BAR domain only protein 1
Chromosomal Location19p13.12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FCHO1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.